Dual functional small molecule probes as fluorophore and ligand for misfolding proteins

Current Organic Chemistry

Volumn 17, Issue 6, 2013, Pages 580-593

  Zhang, Xueli ^a,b   Ran, Chongzhao ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Dual functional probes; Fluorescent imaging; Fluorescent probe; In vivo imaging; Misfolding proteins; Near infrared imaging; Neurodegenerative disease; Neurodegenerative diseases

Indexed keywords

DIAGNOSIS; FLUORESCENCE IMAGING; INFRARED DEVICES; MOLECULES; NEURODEGENERATIVE DISEASES; PROBES; THERMOGRAPHY (IMAGING);

ALZHEIMERS DISEASE; DESTRUCTIVE PROCESS; DUAL FUNCTIONAL PROBE; FLUORESCENT IMAGING; FLUORESCENT PROBES; IN-VIVO IMAGING; MISFOLDING; MISFOLDING PROTEIN; NEAR-INFRARED IMAGING; SMALL MOLECULES;

PROTEINS;

EID: 84877761779     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/1385272811317060004     Document Type: Review

References (121)

1. Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walters, P. The Shape and Structure of Proteins, Fourth Edition edn. New York: Garland Science; 2002.
2. Anfinsen CB: The formation and stabilization of protein structure. Biochem. J., 1972, 128(4), 737-749.
3. Selkoe, D.J. Folding proteins in fatal ways. Nature, 2003, 426(6968), 900-904.
4. Chiti F, Dobson CM: Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem., 2006, 75, 333-366.
5. Hammarstrom, P.; Wiseman, R.L.; Powers, E.T.; Kelly, J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science, 2003, 299(5607), 713-716.
6. Dobson, C.M. Protein folding and misfolding. Nature, 2003, 426(6968), 884-890.
7. Stefani, M.; Dobson, C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. (Berl), 2003, 81(11), 678-699.
8. Dobson, C.M. Principles of protein folding, misfolding and aggregation. Semin. Cell Dev. Biol., 2004, 15(1), 3-16.
9. Masters, S.L.; O'Neill, L.A. Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends. Mol. Med., 2011, 17(5), 276-282.
10. Schapira, A.H. Etiology and pathogenesis of Parkinson disease. Neurol. clin., 2009, 27(3), 583-603.
11. Shastry, B.S. Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci. Res., 2001, 41(1), 5-12.
12. Zhang, K.; Schrag, M.; Crofton, A.; Trivedi, R.; Vinters, H.; Kirsch, W. Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics, 2012, 12(8), 1261-1268.
13. Graff, J.; Rei, D.; Guan, J.S.; Wang, W.Y.; Seo, J.; Hennig, K.M.; Nieland, T.J.; Fass, D.M.; Kao, P.F.; Kahn, M. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature, 2012, 483(7388), 222-226.
14. Babenko, O.; Kovalchuk, I.; Metz, G.A. Epigenetic programming of neurodegenerative diseases by an adverse environment. Brain Res., 2012, 1444, 96-111.
15. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 2006, 443(7113), 787-795.
16. Harvey, R.J.; Skelton, R.M.; Rossor, M.N. The prevalence and causes of dementia in people under the age of 65 years. J. Neurol. Neurosur. Ps., 2003, 74(9), 1206-1209.
17. Bertram, L.; Tanzi, R.E. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat. Rev. Neurosci., 2008, 9(10), 768-778.
18. Rubinsztein, D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature, 2006, 443(7113), 780-786.
19. Berchtold, N.C.; Cotman, C.W. Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiol. Aging, 1998, 19(3), 173-189.
20. Samii, A.; Nutt, J.G.; Ransom, B.R. Parkinson's disease. Lancet, 2004, 363(9423), 1783-1793.
21. Reynaud, E. Protein Misfolding and Degenerative Diseases. Nature Education, 2010, 3(9), 28-30.
22. Stefani, M. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim. Biophys. Acta., 2004, 1739(1), 5-25.
23. Santucci, R.; Sinibaldi, F.; Fiorucci, L. Protein folding, unfolding and misfolding: role played by intermediate States. Mini. Rev. Med. Chem., 2008, 8(1), 57-62.
24. Leandro, P.; Gomes, C.M. Protein misfolding in conformational disorders: rescue of folding defects and chemical chaperoning. Mini. Rev. Med. Chem., 2008, 8(9), 901-911.
25. Luo, S.; Zhang, E.; Su, Y.; Cheng, T.; Shi, C. A review of NIR dyes in cancer targeting and imaging. Biomaterials, 2011, 32(29), 7127-7138.
26. Ntziachristos, V.; Bremer, C.; Weissleder, R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur. Radiol., 2003, 13(1), 195-208.
27. Frangioni, J.V. In vivo near-infrared fluorescence imaging. Curr. Opin. Chem. Biol., 2003, 7(5), 626-634.
28. Hassan, M.; Chernomordik, V.; Zielinski, R.; Ardeshirpour, Y.; Capala, J.; Gandjbakhche, A. In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging. Mol. Imaging, 2012, 11(3), 177-186.
29. Mao, S.Y.; Mullins, J.M. Conjugation of fluorochromes to antibodies. Methods Mol. Biol., 2010, 588, 43-48.
30. Mathis, C.A.; Wang, Y.; Klunk, W.E. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr. Pharm. Design, 2004, 10(13), 1469-1492.
31. Shapiro, M.G.; Westmeyer, G.G.; Romero, P.A.; Szablowski, J.O.; Kuster, B.; Shah, A.; Otey, C.R.; Langer, R.; Arnold, F.H.; Jasanoff, A. Directed evolution of a magnetic resonance imaging contrast agent for noninvasive imaging of dopamine. Nat. Biotechnol., 2010, 28(3), 264-270.
32. Higuchi, M.; Iwata, N.; Matsuba, Y.; Sato, K.; Sasamoto, K.; Saido, T.C. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat. Neurosci., 2005, 8(4), 527-533.
33. Yanagisawa, D.; Amatsubo, T.; Morikawa, S.; Taguchi, H.; Urushitani, M.; Shirai, N.; Hirao, K.; Shiino, A.; Inubushi, T.; Tooyama, I. In vivo detection of amyloid beta deposition using (1)(9)F magnetic resonance imaging with a (1)(9)F-containing curcumin derivative in a mouse model of Alzheimer's disease. Neuroscience, 2011, 184, 120-127.
34. Ran, C.; Zhang, Z.; Hooker, J.; Moore, A. In vivo photoactivation without light: use of Cherenkov radiation to overcome the penetration limit of light. Mol. Imaging Biol., 2012, 14(2), 156-162.
35. Xu, Y.; Chang, E.; Liu, H.; Jiang, H.; Gambhir, S.S.; Cheng, Z. Proof-ofconcept study of monitoring cancer drug therapy with cerenkov luminescence imaging. J. Nucl Med., 2012, 53(2), 312-317.
36. Robertson, R.; Germanos, M.S.; Manfredi, M.G.; Smith, P.G.; Silva, M.D. Multimodal imaging with (18)F-FDG PET and Cerenkov luminescence imaging after MLN4924 treatment in a human lymphoma xenograft model. J. Nucl. Med., 2011, 52(11), 1764-1769.
37. Hu, Z.; Liang, J.; Yang, W.; Fan, W.; Li, C.; Ma, X.; Chen, X.; Li, X.; Qu, X.; Wang, J. et al. Experimental Cerenkov luminescence tomography of the mouse model with SPECT imaging validation. Opt. Express, 2010, 18(24), 24441-24450.
38. Li, C.; Mitchell, G.S.; Cherry, S.R. Cerenkov luminescence tomography for small-animal imaging. Opt. Lett., 2010, 35(7), 1109-1111.
39. Ruggiero, A.; Holland, J.P.; Lewis, J.S.; Grimm, J. Cerenkov luminescence imaging of medical isotopes. J. Nucl. Med., 2010, 51(7), 1123-1130.
40. Selkoe, D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature, 1999, 399(6738 Suppl), A23-31.
41. McLean, C.A.; Cherny, R.A.; Fraser, F.W.; Fuller, S.J.; Smith, M.J.; Beyreuther, K.; Bush, A.I.; Masters, C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol., 1999, 46(6), 860-866.
42. Lue, L.F.; Kuo, Y.M.; Roher, A.E.; Brachova, L.; Shen, Y.; Sue, L.; Beach, T.; Kurth, J.H.; Rydel, R.E.; Rogers, J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol., 1999, 155(3), 853-862.
43. Terry, R.; Masliah, E.; Salmon, D.P.; Butters, N.; De, T.R.; Hill, R.; Hansen, L.A.; Katzman, R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 1991, 30(4), 572-580.
44. Haass, C.; Selkoe, D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol., 2007, 8(2), 101-112.
45. Walsh, D.M.; Selkoe, D.J. A beta oligomers-a decade of discovery. J. Neurochem., 2007, 101(5), 1172-1184.
46. Shankar, G.M.; Li, S.; Mehta, T.H.; Garcia, M.A.; Shepardson, N.E.; Smith, I.; Brett, F.M.; Farrell, M.A.; Rowan, M.J.; Lemere, C.A. et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med., 2008, 14(8), 837-842.
47. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
48. Mawuenyega, K.G.; Sigurdson, W.; Ovod, V.; Munsell, L.; Kasten, T.; Morris, J.C.; Yarasheski, K.E.; Bateman, R.J. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science, 2011, 330(6012), 1774-1776.
49. Klunk, W.E. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol. Aging, 2011, 32 Suppl 1, S20-36.
50. Jakob, R.R.; Jacobsen, H. Alzheimer's disease: from pathology to therapeutic approaches. Angew. Chem. Int. Ed. Engl., 2009, 48(17), 3030-3059.
51. Mathis, C.; Lopresti, B.J.; Klunk, W.E. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl. Med. Biol., 2007, 34(7), 809-822.
52. Kung, M.P.; Hou, C.; Zhuang, Z.P.; Zhang, B.; Skovronsky, D.; Trojanowski, J.Q.; Lee, V.M.; Kung, H.F. IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res., 2002, 956(2), 202-210.
53. Ono, M.; Hayashi, S.; Kimura, H.; Kawashima, H.; Nakayama, M.; Saji, H. Push-pull benzothiazole derivatives as probes for detecting beta-amyloid plaques in Alzheimer's brains. Bioorgan. Med. Chem., 2009, 17(19), 7002-7007.
54. Groenning, M. Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status. J. Chem. Biol., 2009, 3(1), 1-18.
55. Wu, C.; Wang, Z.; Lei, H.; Zhang, W.; Duan, Y. Dual binding modes of Congo red to amyloid protofibril surface observed in molecular dynamics simulations. J. Am. Chem. Soc., 2007, 129(5), 1225-1232.
56. Wu, C.; Wang, Z.; Lei, H.; Duan, Y.; Bowers, M.T.; Shea, J.E. The binding of thioflavin T and its neutral analog BTA-1 to protofibrils of the Alzheimer's disease Abeta(16-22) peptide probed by molecular dynamics simulations. J. Mol. Biol., 2008, 384(3), 718-729.
57. Biancalana, M.; Koide, S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim. Biophys. Acta., 2010, 1804(7), 1405-1412.
58. Biancalana, M.; Makabe, K.; Koide, A.; Koide, S. Molecular mechanism of thioflavin-T binding to the surface of beta-rich peptide self-assemblies. J. Mol. Biol., 2009, 385(4), 1052-1063.
59. Maezawa, I.; Hong, H.S.; Liu, R.; Wu, C.Y.; Cheng, R.H.; Kung, M.P.; Kung, H.F.; Lam, K.S.; Oddo, S.; Laferla, F.M. et al. Congo red and thioflavin-T analogs detect Abeta oligomers. J. Neurochem., 2008, 104(2), 457-468.
60. Alavez, S.; Vantipalli, M.C.; Zucker, D.J.; Klang, I.M.; Lithgow, G.J. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature, 2011, 472(7342), 226-229.
61. Frid, P.; Anisimov, S.V.; Popovic, N. Congo red and protein aggregation in neurodegenerative diseases. Brain Res. Rev., 2007, 53(1), 135-160.
62. Kung, H.F.; Choi, S.R.; Qu, W.; Zhang, W.; Skovronsky, D. 18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. J. Med. Chem., 2010, 53(3), 933-941.
63. Sutharsan, J.; Dakanali, M.; Capule, C.C.; Haidekker, M.A.; Yang, J.; Theodorakis, E.A. Rational design of amyloid binding agents based on the molecular rotor motif. Chem. Med. Chem., 2010, 5(1), 56-60.
64. Hong, M.C.; Kim, Y.K.; Choi, J.Y.; Yang, S.Q.; Rhee, H.; Ryu, Y.H.; Choi, T.H.; Cheon, G.J.; An, G.I.; Kim, H.Y. et al. Synthesis and evaluation of stilbene derivatives as a potential imaging agent of amyloid plaques. Bioorgan. Med. Chem., 2010, 18(22), 7724-7730.
65. Ono, M.; Watanabe, H.; Kimura, H.; Saji, H.; BODIPY-Based Molecular Probe for Imaging of Cerebral β-Amyloid Plaques. ACS Chem. Neurosci., 2012, 3(4), 319-324.
66. Li, Q.; Lee, J.S.; Ha, C.; Park, C.B.; Yang, G.; Gan, W.B.; Chang, Y.T. Solid-phase synthesis of styryl dyes and their application as amyloid sensors. Angew. Chem. Int. Ed. Engl., 2004, 43(46), 6331-6335.
67. Nesterov, E.E.; Skoch, J.; Hyman, B.T.; Klunk, W.E.; Bacskai, B.J.; Swager, T.M. In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew. Chem. Int. Ed. Engl., 2005, 44(34), 5452-5456.
68. Raymond, S.B.; Skoch, J.; Hills, I.D.; Nesterov, E.E.; Swager, T.M.; Bacskai, B.J. Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology. Eur. J. Nucl. Med. Mol. I., 2008, 35 (Suppl 1), s93-98.
69. Jose, J.; Burgess, K. Benzophenoxazine-based fluorescent dyes for labeling biomolecules. Tetrahedron, 2006, 62, 11021-11037.
70. Jose, J.; Loudet, A.; Ueno, Y.; Barhoumi, R.; Burghardt, R.C.; Burgess, K. Intracellular imaging of organelles with new water-soluble benzophenoxazine dyes. Org. Biomol. Chem., 2010, 8, 2052-2058.
71. Hintersteiner, M.; Enz, A.; Frey, P.; Jaton, A.L.; Kinzy, W.; Kneuer, R.; Neumann, U.; Rudin, M.; Staufenbiel, M.; Stoeckli, M. et al. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat. Biotechnol., 2005, 23(5), 577-583.
72. Abelein, A.; Bolognesi, B.; Dobson, C.M.; Graslund, A.; Lendel, C. Hydrophobicity and conformational change as mechanistic determinants for nonspecific modulators of amyloid beta self-assembly. Biochemistry, 2012, 51(1), 126-137.
73. Hard, T.; Lendel, C. Inhibition of Amyloid Formation. J. Mol. Biol., 2012, 421(4-5), 441-465.
74. Mishra, R.; Sjolander, D.; Hammarstrom, P. Spectroscopic characterization of diverse amyloid fibrils in vitro by the fluorescent dye Nile red. Mol. Biosyst., 2011, 7(4), 1232-1240.
75. Shishodia, S.; Sethi, G.; Aggarwal, B.B. Curcumin: getting back to the roots. Ann. N. Y. Acad. Sci., 2005, 1056, 206-217.
76. Siwak, D.R.; Shishodia, S.; Aggarwal, B.B.; Kurzrock, R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signalregulated protein kinase pathway and the Akt pathway. Cancer, 2005, 104(4), 879-890.
77. Aggarwal, B.B.; Shishodia, S.; Takada, Y.; Banerjee, S.; Newman, R.A.; Bueso-Ramos, C.E.; Price, J.E. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res., 2005, 11(20), 7490-7498.
78. Aggarwal, S.; Ichikawa, H.; Takada, Y.; Sandur, S.K.; Shishodia, S.; Aggarwal, B.B. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol. Pharmacol., 2006, 69(1), 195-206.
79. Yang, F.; Lim, G.P.; Begum, A.N.; Ubeda, O.J.; Simmons, M.R.; Ambegaokar, S.S.; Chen, P.P.; Kayed, R.; Glabe, C.G.; Frautschy, S.A. et al: Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem., 2005, 280(7), 5892-5901.
80. Garcia, A.M.; Borrelli, L.A.; Rozkalne, A.; Hyman, B.T.; Bacskai, B.J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem., 2007, 102(4), 1095-1104.
81. Yanagisawa, D.; Taguchi, H.; Yamamoto, A.; Shirai, N.; Hirao, K.; Tooyama, I. Curcuminoid binds to amyloid-beta1-42 oligomer and fibril. J. Alzheimers Dis., 2011, 24(2), 33-42.
82. Ryu, E.K.; Choe, Y.S.; Lee, K.H.; Choi, Y.; Kim, B.T. Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J. Med. Chem., 2006, 49(20), 6111-6119.
83. Ran, C.; Zhao, W.; Moir, R.D.; Moore, A. Non-conjugated small molecule FRET for differentiating monomers from higher molecular weight amyloid beta species. PloS one, 2011, 6(4), e19362.
84. Ran, C.; Xu, X.; Raymond, S.B.; Ferrara, B.J.; Neal, K.; Bacskai, B.J.; Medarova, Z.; Moore, A. Design, synthesis, and testing of difluoroboronderivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits. J. Am. Chem. Soc., 2009, 131(42), 15257-15261.
85. Ran, C.; Moir, R.D.; Moore, A. Curcumin analogues as "turn-on" fluorescent probes for a wide variety of amyloid beta species and in vivo imaging with transgenic mice. World Molecular Imaging Congress, 2010, Kyoto, Japan 2010.
86. Ran, C.; Moore, A. Spectral unmixing imaging of wavelength-responsive fluorescent probes: an application for the real-time report of amyloid Beta species in Alzheimer's disease. Mol. Imaging Biol., 2012, 14(3), 293-300.
87. Cui, M.; Ono, M.; Kimura, H.; Liu, B.; Saji, H. Synthesis and structureaffinity relationships of novel dibenzylideneacetone derivatives as probes for beta-amyloid plaques. J. Med. Chem., 2011, 54(7), 2225-2240.
88. Liu, K.; Guo, T.L.; Chojnacki, J.; Lee, H.G.; Wang, X.; Siedlak, S.L.; Rao, W.; Zhu, X.; Zhang, S. Bivalent ligand containing curcumin and cholesterol as fluorescence probe for Abeta plaques in Alzheimer's disease. ACS Chem. Neurosci., 2012, 3(2), 141-146.
89. Okamura, N.; Mori, M.; Furumoto, S.; Yoshikawa, T.; Harada, R.; Ito, S.; Fujikawa, Y.; Arai, H.; Yanai, K.; Kudo, Y. In vivo Detection of Amyloid Plaques in the Mouse Brain using the Near-Infrared Fluorescence Probe THK-265. J. Alzheimers Dis., 2011, 23(1), 37-48.
90. Cook, N.; Torres, V.; Jain, D.; Martí, A.A. Sensing amyloid-β aggregation using luminescent dipyridophenazine ruthenium(II) complexes. J. Am. Chem. Soc., 2011, 133(29), 11121-11123.
91. Cui, M.; Ono, M.; Kimura, H.; Liu, B.L.; Saji, H. Synthesis and biological evaluation of indole-chalcone derivatives as beta-amyloid imaging probe. Bioorg. Med. Chem. Lett., 2011, 21(3), 980-982.
92. Calignon, A.; Fox, L.M.; Pitstick, R.; Carlson, G.A.; Bacskai, B.J.; Spires-Jones, T.L.; Hyman, B.T. Caspase activation precedes and leads to tangles. Nature, 2010, 464(7292), 1201-1204.
93. Hanger, D.P.; Byers, H.L.; Wray, S.; Leung, K.Y.; Saxton, M.J.; Seereeram, A.; Reynolds, C.H.; Ward, M.A.; Anderton, B.H. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem., 2007, 282(32), 23645-23654.
94. Sperling, R.A.; Aisen, P.S.; Beckett, L.A.; Bennett, D.A.; Craft, S.; Fagan, A.M.; Iwatsubo, T.; Jack, C.R.; Kaye, J.; Montine, T.J. et al Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement., 2011, 7(3), 280-292.
95. Ojida, A.; Sakamoto, T.; Inoue, M.A.; Fujishima, S.H.; Lippens, G.; Hamachi, I. Fluorescent BODIPY-based Zn(II) complex as a molecular probe for selective detection of neurofibrillary tangles in the brains of Alzheimer's disease patients. J. Am. Chem. Soc., 2009, 131(18), 6543-6548.
96. Okamura, N.; Suemoto, T.; Furumoto, S.; Suzuki, M.; Shimadzu, H.; Akatsu, H.; Yamamoto, T.; Fujiwara, H.; Nemoto, M.; Maruyama, M. et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J. Neurosci., 2005, 25(47), 10857-10862.
97. Fodero-Tavoletti, M.T.; Okamura, N.; Furumoto, S.; Mulligan, R.S.; Connor, A.R.; McLean, C.A.; Cao, D.; Rigopoulos, A.; Cartwright, G.A.; O'Keefe, G. et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain: a journal of neurology, 2011, 134(4), 1089-1100.
98. Ferreon, A.C.; Deniz, A.A. Alpha-synuclein multistate folding thermodynamics: implications for protein misfolding and aggregation. Biochemistry, 2007, 46(15), 4499-4509.
99. Arima, K.; Ueda, K.; Sunohara, N.; Hirai, S; Izumiyama, Y.; Tonozuka-Uehara, H.; Kawai, M. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res., 1998, 808(1), 93-100.
100. Arima, K.; Ueda, K.; Sunohara, N.; Arakawa, K.; Hirai, S.; Nakamura, M.; Tonozuka-Uehara, H.; Kawai, M. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol., 1998, 96(5), 439-444.
101. Singleton, A.B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R. et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science, 2003, 302(5646), 841.
102. Volkova, K.D.; Kovalska, V.B.; Balanda, A.O.; Losytskyy, M.Y.; Golub, A.G.; Vermeij, R.J.; Subramaniam, V.; Tolmachev, O.I.; Yarmoluk, S.M. Specific fluorescent detection of fibrillar alpha-synuclein using mono-and trimethine cyanine dyes. Bioorgan. Med. Chem., 2008, 16(3), 1452-1459.
103. Volkova, K.D.; Kovalska, V.B.; Losytskyy, M.Y.; Veldhuis, G.; Segers-Nolten, G.M.; Tolmachev, O.I.; Subramaniam, V.; Yarmoluk, S.M. Studies of interaction between cyanine dye T-284 and fibrillar alpha-synuclein. J. Fluoresc., 2010, 20(6), 1267-1274.
104. Crystal, A.S.; Giasson, B.I.; Crowe, A.; Kung, M.P.; Zhuang, Z.P.; Trojanowski, J.Q.; Lee, V.M. A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J. Neurochem., 2003, 86(6), 1359-1368.
105. Celej, M.S.; Caarls, W.; Demchenko, A.P.; Jovin, T.M. A triple-emission fluorescent probe reveals distinctive amyloid fibrillar polymorphism of wildtype alpha-synuclein and its familial Parkinson's disease mutants. Biochemistry, 2009, 48(31), 7465-7472.
106. Yushchenko, D.A.; Fauerbach, J.A.; Thirunavukkuarasu, S.; Jares-Erijman, E.A.; Jovin, T.M. Fluorescent ratiometric MFC probe sensitive to early stages of alpha-synuclein aggregation. J. Am. Chem. Soc., 2010, 132(23), 7860-7861.
107. Celej, M.S.; Jares-Erijman, E.A.; Jovin, T.M. Fluorescent Narylaminonaphthalene sulfonate probes for amyloid aggregation of alphasynuclein. Biophys J, 2008, 94(12), 4867-4879.
108. Melloul, D.; Marshak, S.; Cerasi, E. Regulation of insulin gene transcription. Diabetologia, 2002, 45(3), 309-326.
109. Furukawa, N.; Shirotani, T.; Nakamaru, K.; Matsumoto, K.; Shichiri, M.; Araki, E. Regulation of the insulin gene transcription by glucose. Endocr. J., 2002, 49(2), 121-130.
110. Brange, J.; Andersen, L.; Laursen, E.D.; Meyn, G.; Rasmussen, E. Toward understanding insulin fibrillation. J. Pharm. Sci., 1997, 86(5), 517-525.
111. Shikama, Y.; Kitazawa, J.; Yagihashi, N.; Uehara, O.; Murata, Y.; Yajima, N.; Wada, R.; Yagihashi, S. Localized amyloidosis at the site of repeated insulin injection in a diabetic patient. Intern. Med., 2010, 49(5), 397-401.
112. Pryor, E.; Kotarek, J.A.; Moss, M.A.; Hestekin, C.N. Monitoring Insulin Aggregation via Capillary Electrophoresis. Int. J. Mol. Sci., 2011, 12(12), 9369-9388.
113. Groenning, M.; Norrman, M.; Flink, J.M.; van de Weert, M.; Bukrinsky, J.T.; Schluckebier, G.; Frokjaer, S. Binding mode of Thioflavin T in insulin amyloid fibrils. J. Struct. Biol., 2007, 159(3), 483-497.
114. Rodriguez-Rodriguez, C.; Rimola, A.; Rodriguez-Santiago, L.; Ugliengo, P.; Alvarez-Larena, A.; Gutierrez-de-Teran, H.; Sodupe, M.; Gonzalez-Duarte, P. Crystal structure of thioflavin-T and its binding to amyloid fibrils: insights at the molecular level. Chem. Commun., 2010, 46(7), 1156-1158.
115. Hong, Y.; Meng, L.; Chen, S.; Leung, C.W.; Da, L.T.; Faisal, M.; Silva, D.A.; Liu, J.; Lam, J.W.; Huang, X. et al. Monitoring and inhibition of insulin fibrillation by a small organic fluorogen with aggregation-induced emission characteristics. J. Am. Chem. Soc., 2012, 134(3), 1680-1689.
116. Kitts, C.C.; Beke-Somfai, T.; Norden, B. Michler's hydrol blue: a sensitive probe for amyloid fibril detection. Biochemistry, 2011, 50(17), 3451-3461.
117. Prusiner, S.B. Prions. Proc. Nati. Acad. Sci. USA, 1998, 95(23), 13363-13383.
118. Ishikawa, K.; Doh-ura, K.; Kudo, Y.; Nishida, N.; Murakami-Kubo, I.; Ando, Y.; Sawada, T.; Iwaki, T. Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J. Gen. Virol., 2004, 85(Pt 6), 1785-1790.
119. Stefansson, S.; Adams, D.L.; Tang, C.M. Common benzothiazole and benzoxazole fluorescent DNA intercalators for studying Alzheimer Abeta1-42 and prion amyloid peptides. Biotechniques, 2012, 0(0), 1-6.
120. Smid, L.M.; Vovko, T.D.; Popovic, M.; Petric, A.; Kepe, V.; Barrio, J.R.; Vidmar, G.; Bresjanac, M. The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. Brain Pathol., 2006, 16(2), 124-130.
121. Cao, K.; Farahi, M.; Dakanali, M.; Chang, W.M.; Sigurdson, C.J.; Theodorakis, E.A.; Yang, J. Aminonaphthlanene 2-Cyanoacrylate (ANCA) Probes Fluorescently Discriminate between Amyloid-beta and Prion Plaques in Brain. J. Am. Chem. Soc., 2012, ASAP, ja3063698.